Editorial

Leukemia (2006) 20, 1481–1483. doi:10.1038/sj.leu.2404291

Treatment of myelodysplastic syndromes with exogenous erythropoietin: a new therapeutic paradigm

S D Mundle1,2 and A Raza3

  1. 1OrthoBiotech Inc., Bridgewater, NJ, USA
  2. 2Rush University Medical Center, Chicago, IL, USA
  3. 3University of Massachusetts Medical School, Worcester, MA, USA

Correspondence: SD Mundle, E-mail: smundle@obius.jnj.com

Extra navigation

.

naturejobs

More science jobs
Post a job for free
ADVERTISEMENT